Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 6/20 | 1.00 |
| ▸ | NT5E | P21589 | 5/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.86 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.83 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21067537 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL14414858 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL29394370 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL15532186 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL29357429 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL16351400 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL24205127 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21724956 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL16674879 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL18351578 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240170-A1 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | WATERS TECHNOLOGIES CORPORATION (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240240170-A1 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | WATERS TECHNOLOGIES CORPORATION (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11912983-B2 | Polyanionic acids to improve recovery and minimize system loss | WATERS TECHNOLOGIES CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912983-B2 | Polyanionic acids to improve recovery and minimize system loss | WATERS TECHNOLOGIES CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | PHARMASSET, LTD. | 2004-09-16 | — | — | US | disclosed |
| EP-0934325-B1 | MYCOPHENOLIC BISPHOSPHONATE COMPOUNDS | PHARMASSET LTD (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1177314-B1 | ASSAYS FOR NUCLEOSIDE DIPHOSPHATES AND TRIPHOSPATES | MEDICAL RES COUNCIL (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6713623-B2 | USEFUL AS INTERMEDIATES IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS | PHARMASSET, LTD. | 2004-03-30 | — | — | US | disclosed |
| US-6326490-B1 | ANTIPROLIFERATION AGENTS OR ANTICARCINOGENIC AGENTS | PHARMASSET, LTD. | 2001-12-04 | — | — | US | disclosed |
| CN-1226169-A | Use of uridine triphosphates and related compounds for prevention and treatment of pneumonia in immobilized patients | INSPIRE PHARMACEUTICALS INC (US) | 1999-08-18 | — | — | CN | disclosed |
| US-5672697-A | FORM OLIGONUCLEOTIDES STABLE TO NUCLEASE DEGRADATION | GILEAD SCIENCES, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ENPP1 481/4885NT5E 3892/4885PLCG1 214/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | ENPP1 481/4885NT5E 3892/4885PLCG1 214/4885 |
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | ENPP1 82/4885NT5E 2263/4885PLCG1 946/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ENPP1 481/4885NT5E 3892/4885PLCG1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.